A man with a long track record of corruption took office as president in January. In his second term, he's surrounding himself with like-minded cabinet secretaries and agency heads. It's a fact that ...

Michelle Xia represents a rising generation of biotech companies in China challenging Western giants.

Merck Foundation marks World Cancer Day with African First Ladies by providing 194 scholarships of Oncology Training to African doctors from 32 countries. Merck Foundation together with Africa First ...

Merck & Co. (MRK) releases positive phase three data for its injectable-form cancer drug Keytruda. Yahoo Finance Senior Health Reporter Anjalee Khemlani joins Market Domination to break down the ...

Merck boasts more than six blockbuster drugs in its portfolio, with blockbuster PD-L1 inhibitor Keytruda being the key top-line driver. Keytruda, approved for several types of cancer, alone ...

In October, Merck took up an option on the personalised RNA-based cancer vaccine with an upfront payment of $250 million as part of a collaboration first agreed in 2016 and expanded in 2018.

With the CSF-1R inhibitor space heating up, Merck KGaA has gone all-in on pimicotinib, paying Abbisko Therapeutics $85 million to secure the global license to the drug. The German pharma ...

Merck & Co has passed another milestone in its drive to move PD-1 inhibitor Keytruda earlier in the treatment pathway for cancer, with the European Commission approving use of the drug as post ...

Animal health is also contributing to growth. Merck boasts a strong cancer pipeline. Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly ...